Regencor is a privately held regenerative medicine company targeting heart disease, the #1 cause of death in the United States. We have discovered and patented that the hypoglycosylated variant of a normal circulating human protein, Follistatin-like 1, (FSTL1) drives heart muscle cells within the infarct zone to undergo controlled proliferation, thereby restoring ventricular contractility, reducing scar volume and preventing progression to heart failure. We are developing two sustained release microsphere formulations of our API, recombinant non-glycosylated human FSTL1 - MyoBeads for delivery to acute MI patients via the infarct related artery at the time of percutaneous coronary revascularization, and Q-Beads, a subcutaneous microsphere formulation of FSTL1 for administration to patients with heart failure. Our core mission is to reduce morbidity and mortality from myocardial infarction, and to prevent the progression to heart failure following MI.
Company Details
- Employees
- 6
- Founded
- -
- Address
- 733 Industrial Road, San Carlos,ca 94070,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- regencor.com
- Keywords
- cardiovascular disease, myocardial infarction, heart failure, cardiac regeneration, alternative glycoforms of Follistatin-like 1, microsphere encapsulation.
- HQ
- San Carlos, CA
Regencor Inc. Questions
Regencor Inc.'s website is regencor.com
Regencor Inc.'s LinkedIn profile is https://www.linkedin.com/company/regencor-inc
Regencor Inc. has
6 employees.
View email and phone details for 6
employees at Regencor Inc..
Regencor Inc.'s industry is
Biotechnology Research
Regencor Inc.'s top competitors are
Focal Pointe Cloud Solutions,
Regentys, Inc.,
Gri Bio, Inc.,
Neuralace Medical®,
Janux Therapeutics,
Kintara Therapeutics, Inc. Nasdaq: Ktra,
Mathews Consulting International,
Regencore,
Sapro Cro,
Ypo.
Regencor Inc.'s categories are Biotechnology Research
Regencor Inc.'s founding year is 2015
